EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Partnerships
PrecisionLife and Nxera Pharma expand partnership to target auto-immune disorders drug discovery
Precision Medicine
May 30, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Partnerships
Product updates
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Precision Medicine

Precision Medicine

May 30, 2024

PrecisionLife and Nxera Pharma expand partnership to target auto-immune disorders drug discovery

Partnerships

  • PrecisionLife and Nxera Pharma have expanded their collaborative partnership to potentially discover new drug targets for treating auto-immune disorders. The collaboration was announced as an extension of the companies' existing partnership, established in 2022.

  • The partnership aims to establish precision-targeted therapies for auto-immune disorders. PrecisionLife's disease insights and stratification biomarkers will be used to identify patient subgroups, enabling Nxera to determine suitable drug targets accurately. This collaboration aims to leverage the combined strengths of both companies to develop effective treatments for complex diseases in the future.

  • UK-based PrecisionLife specializes in generating biological insights into complex chronic diseases. Leveraging its AI-led Innovation Engine and combinatorial analytics, the company aims to accelerate drug development and personalize healthcare by identifying disease mechanisms relevant to specific patients. The company’s services include discovering novel drug targets, enriching clinical trials, and creating personalized diagnostics.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.